Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring

Abstract The aim of this prospective, randomized, open-label, masked, endpoint, crossover study was to compare the antihypertensive efficacy of valsartan with that of losartan—angiotensin II (Ang II) receptor antagonists with different pharmacologic profiles—in patients with mild-to-moderate essential hypertension. After an initial 2-week placebo washout period, 40 patients (24 men and 16 women, aged 39 to 58 years) were assigned randomly to receive valsartan 80 mg or losartan 50 mg once daily for 4 weeks. After an intermediate 2-week placebo washout period, patients were switched to the alternative regimen for an additional 4 weeks. After the initial placebo washout period and every 2 weeks thereafter, 24-hour ambulatory blood pressure monitoring (ABPM) was performed using a noninvasive device, and casual blood pressure (BP) and heart rate were measured. Both losartan and valsartan had a clear-cut antihypertensive effect. However, valsartan showed significantly better antihypertensive efficacy compared with that of losartan, as demonstrated by (1) the 24-hour, daytime, and nighttime ABPM values, which were significantly lower ( P

[1]  M. de Gasparo,et al.  Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects , 1997, European Journal of Clinical Pharmacology.

[2]  S. Whitebread,et al.  Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype , 1993, British journal of pharmacology.

[3]  T. Hedner,et al.  Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.

[4]  K. Bailey,et al.  Blood pressure load--a better determinant of hypertension. , 1988, Mayo Clinic proceedings.

[5]  G Parati,et al.  Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. , 1995, Blood pressure.

[6]  Giuseppe Mancia,et al.  Ambulatory Blood Pressure Is Superior to Clinic Blood Pressure in Predicting Treatment-Induced Regression of Left Ventricular Hypertrophy , 1997 .

[7]  Y. Christen,et al.  Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist , 1992, Clinical pharmacology and therapeutics.

[8]  G. Schillaci,et al.  Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. , 1990, Circulation.

[9]  Stephen Senn,et al.  Cross-over trials in clinical research , 1993 .

[10]  F. Guengerich,et al.  Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[11]  P. Srivastava,et al.  Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. , 1989, The Journal of biological chemistry.

[12]  Steven Whitebread,et al.  Binding of valsartan to mammalian angiotensin AT1 receptors , 1995, Regulatory Peptides.

[13]  K. Goa,et al.  Valsartan , 1997, Drugs.

[14]  T. Bjornsson,et al.  Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans , 1995, Clinical pharmacology and therapeutics.

[15]  D. Snavely,et al.  Blood pressure effects of the angiotensin II receptor blocker, losartan. , 1995, Archives of internal medicine.

[16]  W. A. Bradley,et al.  Valsartan: Preclinical and Clinical Profile of an Antihypertensive Angiotensin‐II Antagonist , 1995 .

[17]  D. Triggle.  Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. , 1995, Clinical therapeutics.

[18]  W. White,et al.  Blood pressure load and target organ effects in patients with essential hypertension. , 1991, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[19]  K. Bailey,et al.  Age-related characteristics of ambulatory blood pressure load and mean blood pressure in normotensive subjects. , 1991, JAMA.

[20]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.

[21]  M. de Gasparo,et al.  Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.